版本:
中国

BRIEF-Lilly announces strategic collaboration with Keybioscience

June 8 Eli Lilly And Co

* Lilly announces strategic collaboration with Keybioscience AG

* Eli Lilly and Co - under terms of agreement, Lilly will receive worldwide rights to develop and commercialize these molecules

* Eli Lilly and Co - ‍under terms of agreement, Lilly will receive worldwide rights to develop and commercialize these molecules​

* Says collaboration includes access to Dacra platform with multiple molecules including KBP-042, KBP-089 and KBP-056

* Eli Lilly and Co - there will be no change to company's FY non-GAAP earnings per share guidance as a result of this transaction

* Says Keybioscience has initiated phase 2 development with KBP-042

* Eli Lilly and Co - expects to incur an acquired in-process research and development charge to earnings in 2017 of approximately $0.03 per share

* To incur an acquired in-process research and development charge to earnings in 2017 of approximately $0.03 per share.

* In exchange for these rights, Keybioscience will receive an initial payment of $55 million

* Eli Lilly and Co - co, Keybioscience AG have agreed to a new collaboration focused on development of dual Amylin Calcitonin receptor agonists​ Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐